TargeGen Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $201M
Latest Deal Amount

TargeGen General Information

Description

Developer of small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 9380 Judicial Drive
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TargeGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Jul-2010 $201M 00000 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 12-Jul-2007 000.00 00000 00000 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 31-Aug-2005 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 13-Jan-2004 $30.6M $40.6M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 03-Apr-2002 $10M $10M 0000 Completed Product Development
To view TargeGen’s complete valuation and funding history, request access »

TargeGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 000
Series B 27,061,947 $0.000100 $0.09 $1.13 $1.13 1x $1.13 22.55%
Series A 10,000,000 $0.000100 $0.08 $1 $1 1x $1 8.33%
To view TargeGen’s complete cap table history, request access »

TargeGen Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BB Biotech Ventures Venture Capital Minority 000 0000 000000 0
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Chicago Growth Partners PE/Buyout Minority 000 0000 000000 0
Enterprise Partners Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »